BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 11249571)

  • 1. Linezolid Pharmacia Corp.
    Barrett JF
    Curr Opin Investig Drugs; 2000 Oct; 1(2):181-7. PubMed ID: 11249571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of linezolid versus comparator therapies in Gram-positive infections.
    Wilcox MH
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii27-35. PubMed ID: 12730140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
    Krueger WA; Unertl KE
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
    Kaplan SL; Afghani B; Lopez P; Wu E; Fleishaker D; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S178-85. PubMed ID: 14520144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Have the oxazolidinones lived up to their billing? Future perspectives for this antibacterial class.
    Nilius AM
    Curr Opin Investig Drugs; 2003 Feb; 4(2):149-55. PubMed ID: 12669374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linezolid.
    Narang M; Gomber S
    Indian Pediatr; 2004 Nov; 41(11):1129-32. PubMed ID: 15591662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of linezolid in children: an overview of recent advances.
    Velissariou IM
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
    Deville JG; Adler S; Azimi PH; Jantausch BA; Morfin MR; Beltran S; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S158-63. PubMed ID: 14520141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
    Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
    J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid, the first oxazolidinone antibacterial agent.
    Leach KL; Brickner SJ; Noe MC; Miller PF
    Ann N Y Acad Sci; 2011 Mar; 1222():49-54. PubMed ID: 21434942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telithromycin. Aventis Pharma.
    Johnson AP
    Curr Opin Investig Drugs; 2001 Dec; 2(12):1691-701. PubMed ID: 11892930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].
    Jahoda D; Nyc O; Pokorný D; Landor I; Sosna A
    Acta Chir Orthop Traumatol Cech; 2006 Oct; 73(5):329-33. PubMed ID: 17140514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
    Stevens DL; Herr D; Lampiris H; Hunt JL; Batts DH; Hafkin B
    Clin Infect Dis; 2002 Jun; 34(11):1481-90. PubMed ID: 12015695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tedizolid: a new oxazolidinone antimicrobial.
    Kisgen JJ; Mansour H; Unger NR; Childs LM
    Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of linezolid in children.
    Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program.
    Anderegg TR; Sader HS; Fritsche TR; Ross JE; Jones RN
    Int J Antimicrob Agents; 2005 Jul; 26(1):13-21. PubMed ID: 15967640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linezolid resistance in sequential Staphylococcus aureus isolates associated with a T2500A mutation in the 23S rRNA gene and loss of a single copy of rRNA.
    Meka VG; Pillai SK; Sakoulas G; Wennersten C; Venkataraman L; DeGirolami PC; Eliopoulos GM; Moellering RC; Gold HS
    J Infect Dis; 2004 Jul; 190(2):311-7. PubMed ID: 15216466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linezolid for the treatment of drug-resistant infections.
    Herrmann DJ; Peppard WJ; Ledeboer NA; Theesfeld ML; Weigelt JA; Buechel BJ
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):825-48. PubMed ID: 19053895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of linezolid in the treatment of complicated skin and soft tissue infections.
    Peppard WJ; Weigelt JA
    Expert Rev Anti Infect Ther; 2006 Jun; 4(3):357-66. PubMed ID: 16771613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Linezolid resistance in Staphylococcus aureus: characterization and stability of resistant phenotype.
    Pillai SK; Sakoulas G; Wennersten C; Eliopoulos GM; Moellering RC; Ferraro MJ; Gold HS
    J Infect Dis; 2002 Dec; 186(11):1603-7. PubMed ID: 12447736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.